Home-based Bimodal Lifestyle Intervention in Patients With Liver Cirrhosis Awaiting Orthotopic Liver Transplantation
NCT ID: NCT05853484
Last Updated: 2024-05-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
16 participants
INTERVENTIONAL
2024-09-01
2025-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing LiverWatch, a Home-Based Remote-Monitoring Intervention for Advanced Liver Disease
NCT06136221
Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis
NCT05033327
Impact of Nutritional Management on the Frailty of Patients Waiting for Liver Transplantation (Via the LFI Tool)
NCT06911619
The Impact of Liver Cirrhosis on Outcomes in Trauma Patients
NCT05170854
Molecular Mechanism of Exercise in Cirrhosis
NCT05982769
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective: The primary objective of this study is to assess the effect of a semi-supervised home based bimodal lifestyle intervention on aerobic capacity (measured by VO2 at the Ventilatory anaerobic threshold (VAT) and VO2peak in ml/kg/min) in patients with liver cirrhosis on the waiting list for OLT. Secondary objectives are to evaluate individual patients' responses to the bimodal lifestyle intervention on sarcopenia, anthropometry, functional mobility, quality of life, perceived fatigue, incidence of hepatic encephalopathy, number of unplanned hospital admissions, change in liver frailty index score and change in microbiome composition at six, 12 and 18 weeks, or until transplantation. Finally, the feasibility (participation rate, reasons for non-participation, adherence/compliance, dropout rate, reasons for dropout and adverse event) will be assessed.
Study design: This study is an investigator-initiated, single center, single arm, prospective clinical trial. It will take place at the University Medical Center Groningen, the Netherlands. Eligible patients will participate in the bimodal lifestyle program, which comprises two home-based training periods of six-weeks each (12 weeks training in total, or until transplantation). After 18 weeks (i.e., six weeks after termination of the program) a final assessment will take place to evaluate the longevity of the expected effects of the lifestyle program on predefined study outcomes.
Study population: Adult patients diagnosed with liver cirrhosis and screened for OLT, with a VO2 at the VAT ≤13ml/kg/min and/or VO2peak ≤18ml/kg/min will be screened for potential eligibility. Patients with no contraindications to physical exercise training and the ability to work out on a cycle ergometer can participate in the bimodal lifestyle intervention.
Intervention: Patients will participate in a home-based bimodal lifestyle program. The program comprises semi-supervised high intensity interval and endurance training on an advanced cycle ergometer (Lode Corival Home+ , Lode BV, Groningen, The Netherlands), combined with nutritional support consisting of protein, vitamin and mineral supplementation. Moreover, to improve functional mobility and muscle function patients will perform peripheral resistance training of the large muscle groups of the upper and lower extremities. Finally, to improve respiratory performance after surgery and potentially reduce pulmonary complications, patients will perform breathing exercises. The program will be patient personalized and compromises three training sessions per week. The cycle ergometer used for this program will upload training results of the interval and endurance training sessions to an online platform, enabling remote monitoring of patients' adherence and training progress. Furthermore, a community physical therapist will visit the patient at least weekly to monitor progress and to optimize the training intensity.
Main study parameters/endpoints: The main study parameter/endpoint is the progression in aerobic capacity after 6 weeks. Hereto, before and after the first training period a CPET will performed to determine the difference in VO2 at the VAT and VO2peak in ml/kg/min. A secondary parameter/endpoint of this study is the progression in aerobic capacity after the second training period, and six weeks after termination of the program. Hereto, after 12 and 18 weeks another CPET will be performed. Other secondary parameters/endpoints are the evaluation of differences in sarcopenia, anthropometry, functional mobility, quality of life, perceived fatigue, incidence of hepatic encephalopathy, number of unplanned hospital admissions, change in liver frailty index score and change in microbiome composition at six, 12 and 18 weeks, or until transplantation. Furthermore, postoperative outcomes up to twelve months post-OLT will be collected.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Because the exercise program is situated at home (both the cycle ergometer as the community physiotherapist will come to the patient) the investigators make things as accessible as possible for the patient to participate. Supervision by the physiotherapist during the training sessions is arranged three times in the first week and at least once a week thereafter. At the start of the program a CPET with continuous ECG monitoring will be executed under guidance of trained employees to assess baseline cardiorespiratory fitness, as well as to rule out strain related cardiac ischemia and other contraindications for physical exercise training during the consecutive exercise program. Hence, patient's safety in the exercise program is guaranteed. To minimize the burden of this study, the majority of the visits, withdrawal of blood samples, physical examinations and other study procedures, are combined with regular outpatient clinic visits.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Home based prehabilitation
Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
Bimodal lifestyle program
Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bimodal lifestyle program
Participants will be subjected to two training periods of six weeks (or until transplantation) of a semi-supervised home-based bimodal lifestyle program. The bimodal lifestyle program consists of an exercise program combined with nutritional support. The exercise program comprises high intensity interval training and endurance training, combined with peripheral resistance training and breathing exercises
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with end-stage liver disease / liver cirrhosis (regardless of etiology);
* On the waiting list for OLT;
* VO2 at the VAT ≤13 ml/kg/min and/or VO2peak ≤18 ml/kg/min;
* Speaks the Dutch language;
* Understands the purpose of the study and has given written informed consent to participate in the study.
Exclusion Criteria
* Experienced a cerebrovascular incident in the past six months;
* Medical history of an uncontrolled heart rhythm disorder;
* Hepatic encephalopathy grade 3 or 4;
* Acute liver failure;
* Acute on chronic liver failure;
* Hospitalization at start of the study;
* Non-treated esophageal varices (i.e., variceal eradication endoscopy and/or adequately dosed NSBB);
* MELD score ≥30;
* Not capable of cycling on a cycle ergometer;
* No available community physical therapist in the living area of the patient.
* Patients refusing or unable to sign informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wijma AG, Bongers BC, Annema C, Dekker R, Blokzijl H, van der Palen JA, De Meijer VE, Cuperus FJ, Klaase JM. 'Effects of a home-based bimodal lifestyle intervention in frail patients with end-stage liver disease awaiting orthotopic liver transplantation': study protocol of a non-randomised clinical trial. BMJ Open. 2024 Jan 29;14(1):e080430. doi: 10.1136/bmjopen-2023-080430.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NL83612.042.23
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.